Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas
Jenna L Gordon1, Kristin J Hinsen2, Melissa M Reynolds3
1Department of Chemistry, Colorado State University, Fort Collins, CO 80521, USA.
Abstract:
Despite enormous advances in the detection and treatment of breast cancer, it still remains the leading cancer diagnosis and has the second highest mortality rate. Thus, breast cancer research is a high priority for academics and clinicians alike. Based on previous research indicating the potential of nitric oxide (NO) and SMYD-3 inhibition, this work sought to expand upon these concepts and combine the two approaches. Both NO (from S-Nitrosoglutathione (GSNO)), termed Group 1, and a combination therapeutic, inhibitor-4 (SMYD-3 inhibitor) plus NO (from GSNO), termed Group 2, were evaluated for their efficacy on breast carcinoma cell lines MCF7 and MDA-MB-231, and the normal MCF10A breast cell line, using cellular viability, colony formation capacity, cytotoxicity, and cellular apoptosis analysis. These results indicated that, in Group 1, breast carcinoma lines MCF7 and MDA-MB-231, cells experienced a moderate reduction in cellular viability (~20-25%), a large reduction in colony formation capacity (~80-90%), a moderate increase in the relative number of dead cells, and a moderate increase in cellular apoptosis. Group 2 was significantly more impactful, with a ~50% knockdown in cellular viability, a 100% reduction in colony formation capacity, a large increase in the relative number of dead cells, and a large increase in cellular apoptosis. Additionally, Group 2 induced a very small impact on the normal MCF10A cell line. Cumulatively, this work revealed the exciting impact of this combination therapeutic, indicating its potential for clinical application and further research.
Insights
A novel combination therapy using nitric oxide (NO) and a SMYD-3 inhibitor significantly reduced breast cancer cell viability and colony formation while sparing normal cells, showing promise for clinical applications.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer remains a leading cause of cancer diagnosis and mortality, necessitating novel therapeutic strategies.
- Nitric oxide (NO) and SMYD-3 inhibition have shown individual promise in preclinical cancer research.
- Combining these approaches may offer enhanced efficacy against breast carcinoma.
Purpose of the Study:
- To evaluate the efficacy of nitric oxide (NO) alone and in combination with a SMYD-3 inhibitor on breast cancer cell lines.
- To assess the impact of the combination therapy on normal breast cell lines.
- To determine the potential clinical applicability of this combined therapeutic approach.
Main Methods:
- Utilized breast carcinoma cell lines (MCF7, MDA-MB-231) and a normal breast cell line (MCF10A).
- Administered nitric oxide (NO) via S-Nitrosoglutathione (GSNO) and a SMYD-3 inhibitor (inhibitor-4).
- Assessed cellular viability, colony formation capacity, cytotoxicity, and apoptosis.
Main Results:
- Group 1 (NO alone) showed moderate reductions in cancer cell viability (~20-25%) and significant reductions in colony formation (~80-90%).
- Group 2 (SMYD-3 inhibitor + NO) demonstrated substantial efficacy: ~50% viability reduction, 100% colony formation inhibition, increased cell death, and apoptosis.
- Group 2 exhibited minimal impact on the normal MCF10A cell line.
Conclusions:
- The combination of SMYD-3 inhibition and nitric oxide (NO) is a highly effective therapeutic strategy against breast cancer.
- This combination therapy demonstrates significant anti-cancer effects with a favorable safety profile for normal cells.
- The findings support further research and potential clinical translation of this novel breast cancer treatment.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:23Abnormal Proliferation